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Multiple Sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central
nervous system, and the second cause of neurological disability after trauma in young adults in
the Western world. The efficacy of disease-modifying treatments (DMTs) in relapsing-remitting
(RR) and secondary-progressive (SP) MS is usually surrogated by assessing new/enlarged T2
and gadolinium (Gd)-enhancing lesions on magnetic resonance imaging (MRI) scans. More
recently, brain atrophy has been incorporated as an outcome measure in MS clinical trials due
to its reproducibility, correlation with disability, and detectability from early disease stages. Brain
atrophy measures, however, could lead to equivocal conclusions if a series of factors are not taken
into account, particularly the influence of inflammation.
Some clinical trials evaluating the effects of the same drugs on brain atrophy reported conflicting
results between them, which have been mainly attributed to the inclusion of heterogenous patient
populations, and/or the use of different MRI acquisitions and post-processing methods (De Stefano
et al., 2014). A recent systematic review and meta-analysis of 12 studies evaluating the effects
of first-generation DMTs on annualized percentage brain volume change (PBVC) over at least
12-month follow-up by Structural Image Evaluation of Normalized Atrophy algorithm reported
that its pooled value was similar between treated and untreated patients (−0.69 and −0.71%,
respectively; Vollmer et al., 2015). Another meta-analysis, which included four large studies
involving RRMS cases, showed only modest beneficial effects of DMTs on PBVC (Tsivgoulis et al.,
2015). Drug effects were greater during the second year than the first year of therapy and linearly
increased with therapy prolongation, with no heterogeneity across trials using different DMTs or
various neuroimaging protocols (Tsivgoulis et al., 2015).
Here, we discuss the potential factors related to the presence of inflammation that could
influence brain volume evolution in MS, both in the short- and long-term, and explain, at least
in part, the conflicting results on the neuroprotective effects of DMTs.
First, the “pseudoatrophy” phenomenonmust be taken into account when brain volume changes
are used to evaluate DMTs’ neuroprotective effects in MS clinical trials. This phenomenon, which
occurs during the first 6 months up to a year from beginning of therapy, is due to resolution of the
on-going inflammation, and is predominant for DMTs with strong anti-inflammatory properties.
Due to the “pseudoatrophy” phenomenon, DMTs’ positive effects on brain atrophy compared
with placebo are usually more evident in the second year of therapy (De Stefano et al., 2014).
As “pseudoatrophy” is believed to reflect fluid shifts and resolution of oedema rather than true
tissue loss, this short-term phenomenon can lead to misinterpretation of brain atrophy results if
the baseline brain volume coincides with treatment onset. Interestingly, different DMTs exhibit
“pseudoatrophy” effects of variable entity, though in all cases the effect is prevalent in MS patients
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with evidence of active inflammation at baseline. For example,
in clinical trials evaluating the efficacy of fingolimod, evidence
of “pseudoatrophy” was found only in the subgroup of patients
who showed active inflammation at baseline (Radue et al., 2015).
As there is still much to learn about “pseudoatrophy” and its
dynamics, it might be appropriate to state that within the first
6 months of starting DMTs, early changes of brain volume are
unlikely to reflect true tissue loss and should be interpreted with
caution. In light of this, it seems appropriate that for assessing
brain atrophy changes under DMTs, the baseline brain volume
should be calculated from MRI scans acquired at 6 months after
the beginning of therapy.
It has been suggested that gray matter (GM) volume loss in
MS could be a more sensitive indicator of disease progression
than white matter (WM) atrophy, as “pseudoatrophy” effects are
greater in WM due to its larger inflammatory activity, which
is accompanied by blood-brain barrier breakdown, local fluid
leakage, and increased brain perfusion (Koudriavtseva et al.,
2015). These processes are less evident in GM, which is usually
characterized by decreased vascular perfusion. Furthermore,
GM atrophy rate increases as disease progresses, whereas WM
changes tend to remain substantially similar across disease stages
(De Stefano et al., 2014). Indeed, a recent study re-evaluating
the effect of interferon-beta-1a on GM and WM fractions over
2 years showed that GM change is the most accurate index of
tissue loss and disability progression, although the study used
5mm thick slices, which might not be adequate for measuring
reliably GM atrophy (Fisher et al., 2016).
In SPMS, a disease stage predominantly characterized by
GMneurodegenerative pathological processes, assessment of GM
volume loss would be the most appropriate tool for evaluating
neuroprotective drug effects (Geurts et al., 2009). Furthermore,
it might be worthwhile assessing the GM atrophy in past
DMTs trials in RRMS (Fisher et al., 2016) to reduce potential
“pseudoatrophy” confounding effects that prevail in the WM.
This could allow to elucidate whether the neuroprotective effects
of some DMTs in RRMS are greater than originally thought
(Tsivgoulis et al., 2015; Vollmer et al., 2015). Methods for
standardizing GM atrophy assessments, however, are still lacking,
and the imaging resolution used in clinical trials is usually not
adequate for accurate GM volume measurements, especially in
the cortex.
Finally, another aspect that could account for the limitations
for using brain atrophy measures in DMTs clinical trials in
MS derives from the complex relationship between the degree
and extent of inflammatory activity and brain volume changes,
which seems to extend far beyond the short-term pseudoatrophy
phenomenon, regardless of therapy. For example, the effects
of baseline brain inflammatory activity in RRMS represented
by MRI gadolinium enhancement at the onset of natalizumab
therapy resulted in greater brain tissue loss compared to cases
with no evidence of MRI baseline inflammation at 12- and
24-month follow-up but not at 36-month follow-up (Sastre-
Garriga et al., 2015). Similarly, a previous work investigating
36-month interferon-beta effect on brain atrophy in SPMS
showed that drug effects as compared to placebo were detected
only in patients with no baseline Gd-enhancing lesions, whereas
there was a trend toward a greater atrophy in treated patients
compared to placebo patients having at least one baseline Gd-
enhancing lesion (Molyneux et al., 2000). Furthermore, the
rate of brain atrophy over 2 years in three pivotal phases in
three studies evaluating the efficacy of fingolimod therapy in
RRMS was found to be influenced by both baseline and on-
study disease activity (Radue et al., 2015). Specifically, both high
baseline T2 lesion volume and Gd-enhancing lesion count were
identified as the best predictors of greater PBVC, whereas high
T1-hypointense lesion and low normalized brain volumes were
weaker negative baseline predictors. These findings suggest that
whole-brain atrophy over the 2-year follow-up is influenced
mainly by recent and, to a lesser extent, by remote disease
activity (Radue et al., 2015). Interestingly, in one of these studies
(placebo-controlled trial of oral fingolimod FREEDOMS), the
PBVC was also predicted by the number of relapses occurring
in both 1- and 2-year periods preceding the study (Radue et al.,
2015). Despite the fact that fingolimod reduced the annual
brain atrophy rate by approximately one-third compared with
other trial groups, an influence of baseline disease activity was
reported not only in the treated group (fingolimod, interferon-
beta-1a) but also in the placebo group, thereby indicating its
conditioning on brain atrophy regardless of therapy. On-study
disease activity including cumulative number of Gd-enhancing
lesions, number of both T2 new/enlarged lesions, and confirmed
relapses were also correlated with the PBVC (Radue et al.,
2015).
These findings strongly support for including baseline
T2 lesion load, Gd-enhancing lesion count, and number
of previous relapses in both randomization and statistical
modeling of clinical trials in MS that include brain atrophy
as endpoint. A recent MS-STAT trial reported a protective
effect of simvastatin on brain atrophy and disability in
SPMS (Chataway et al., 2014). In this study, however, the
placebo group compared with the simvastatin-treated one had,
apparently, more active disease by means of greater number
of relapses in the previous 12 and 24 months, and greater
on-study rate of T2 new/enlarging lesions. Unfortunately, in
this study, baseline T2 lesion load and Gd-enhancing lesion
count were not reported. These limitations may, thus, leave
some reservations about the protective effects of simvastatin on
neurodegeneration, as they simply could reflect the consequence
of less baseline and on-study disease activity in the treated
group.
Indeed, MS patients with higher levels of disease
activity (expressed by either the presence of Gd-enhancing
lesions, new T2 lesions, and/or clinical relapses) tend
to have greater rates of brain atrophy, and this is a
consistent finding across different trials, treatment arms,
and disease subtypes. This correlation is likely related to
the dynamics of MS pathologic processes: inflammation
determines demyelination that likely leads to neuroaxonal
degeneration and tissue loss, which in turn is reflected by
brain volume loss on MRI. Hence, for the most part, the
neuroprotective effects of DMTs in MS might be secondary to
a reduction of inflammatory damage and, therefore, delayed in
time.
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In conclusion, the presence of on-going inflammatory activity
leads to a fluctuation in whole brain, and mostly in WM
volume, due to both fluid and inflammatory infiltrates.
Paradoxically, alleviation of this inflammation causes a
pronounced atrophy in the first treatment period (so-called
“pseudoatrophy”). In the longer term, inflammation might
bring to greater demyelination and neuroaxonal degeneration,
leading to larger brain tissue loss. This suggests that the
neuroprotective effects of most DMTs might be largely
secondary to their anti-inflammatory effects with delayed
reduction of atrophy rate, and this needs to be accounted
for when evaluating potential neuroprotective effects of these
therapies.
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